Airway wall thickness is increased in COPD patients with bronchodilator responsiveness

Respiratory Research

Volumn 15, Issue 1, 2014, Pages

  Kim, Victor ^a   Desai, Parag ^a   Newell, John D ^b   Make, Barry J ^c   Washko, George R ^d   Silverman, Edwin K ^d   Crapo, James D ^c   Bhatt, Surya P ^e   Criner, Gerard J ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c DEPARTMENT OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Airflow obstruction; Airway wall thickness; Bronchodilator responsiveness; Chronic obstructive pulmonary disease

Indexed keywords

BRONCHODILATING AGENT;

ADULT; AIRWAY OBSTRUCTION; AIRWAY WALL THICKNESS; ARTICLE; ASTHMA; BODE SCORE; BRONCHODILATOR RESPONSIVENESS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONE BEAM COMPUTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE EXACERBATION; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL RESIDUAL CAPACITY; GAS TRAPPING; GENDER; HUMAN; LUNG EMPHYSEMA; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OBSERVATIONAL STUDY; PREDICTOR VARIABLE; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; RACE; RESPIRATORY TRACT PARAMETERS; SCORING SYSTEM; SMOKING; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TOTAL LUNG CAPACITY; TREATMENT RESPONSE; WALK DISTANCE; WALKING; AGED; CLINICAL TRIAL; DRUG EFFECTS; LUNG; MIDDLE AGED; MULTICENTER STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RADIOGRAPHY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84905985409     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-014-0084-3     Document Type: Article

References (35)

1. Global Initiative for Chronic Obstructive Pulmonary Disease: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, executive summary 2005. 2005, .., www.goldcopd.com
2. Orie NG. The dutch hypothesis. Chest 2000, 117(5 Suppl 1):299S. 10843963.
3. Barnes PJ. Mechanisms in COPD: differences from asthma. Chest 2000, 117(2 Suppl):10S-14S. 10673467.
4. Vermeire PA, Pride NB. A "splitting" look at chronic nonspecific lung disease (CNSLD): common features but diverse pathogenesis. Eur Respir J 1991, 4(4):490-496. 1855578.
5. Dorinsky PM, Reisner C, Ferguson GT, Menjoge SS, Serby CW, Witek TJ. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999, 115(4):966-971. 10208193.
6. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Dorinsky PM, Reisner C, Ferguson GT, Menjoge SS, Serby CW, Witek TJ. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 166(8):1084-1091. 12379552.
7. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer D. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359(15):1543-1554. 18836213.
8. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003, 58(8):659-664. 12885978.
9. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, Macnee W, Miller BE, Silverman EK, Tal-Singer R, Wouters E, Rennard SI. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011, 365(13):1184-1192. 21991892.
10. Vollmer WM, Johnson LR, Buist AS. Relationship of response to a bronchodilator and decline in forced expiratory volume in one second in population studies. Am Rev Respir Dis 1985, 132(6):1186-1193. 4073660.
11. Postma DS, Gimeno F, van der Weele LT, Sluiter HJ. Assessment of ventilatory variables in survival prediction of patients with chronic airflow obstruction: the importance of reversibility. Eur J Respir Dis 1985, 67(5):360-368. 3878797.
12. Postma DS, De Vries K, Koeter GH, Sluiter HJ. Independent influence of reversibility of air-flow obstruction and nonspecific hyperreactivity on the long-term course of lung function in chronic air-flow obstruction. Am Rev Respir Dis 1986, 134(2):276-280. 2874759.
13. Brutsche MH, Downs SH, Schindler C, Gerbase MW, Schwartz J, Frey M, Russi EW, Ackermann-Liebrich U, Leuenberger P. Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study. Thorax 2006, 61(8):671-677. 16670173.
14. Nishimura M, Makita H, Nagai K, Konno S, Nasuhara Y, Hasegawa M, Shimizu K, Betsuyaku T, Ito YM, Fuke S, Igarashi T, Akiyama Y, Ogura S. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 185(1):44-52. 22016444.
15. Kim V, Rogers TJ, Criner GJ. New concepts in the pathobiology of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008, 5(4):478-485. 18453359.
16. Finkelstein R, Fraser RS, Ghezzo H, Cosio MG. Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med 1995, 152(5 Pt 1):1666-1672. 7582312.
17. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350(26):2645-2653. 15215480.
18. Kim V, Kelemen SE, Abuel-Haija M, Gaughan J, Sharafkhaneh A, Evans CM, Dickey BF, Solomides CC, Rogers TJ, Criner GJ. Small airway mucous metaplasia and inflammation in chronic obstructive pulmonary disease. J COPD 2008, 5(6):329-338.
19. Nakano Y, Muro S, Sakai H, Hirai T, Chin K, Tsukino M, Nishimura K, Itoh H, Pare PD, Hogg JC, Mishima M. Computed tomographic measurements of airway dimensions and emphysema in smokers. correlation with lung function. Am J Respir Crit Care Med 2000, 162(3 Pt 1):1102-1108. 10988137.
20. Hasegawa M, Nasuhara Y, Onodera Y, Makita H, Nagai K, Fuke S, Ito Y, Betsuyaku T, Nishimura M. Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173(12):1309-1315. 16556695.
21. Patel BD, Coxson HO, Pillai SG, Agusti AG, Calverley PM, Donner CF, Make BJ, Muller NL, Rennard SI, Vestbo J, Wouters EF, Hiorns MP, Nakano Y, Camp PG, Nasute Fauerbach PV, Screaton NJ, Campbell EJ, Anderson WH, Pare PD, Levy RD, Lake SL, Silverman EK, Lomas DA. Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 178(5):500-505. 18565956.
22. Regan EA, Hokanson JE, Murphy JR, Make B, Lynch DA, Beaty TH, Curran-Everett D, Silverman EK, Crapo JD. Genetic epidemiology of COPD (COPDGene) study design. COPD 2010, 7(1):32-43. 20214461.
23. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999, 159(1):179-187. 9872837.
24. Hanania NA, Sharafkhaneh A, Celli B, Decramer M, Lystig T, Kesten S, Tashkin D. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res 2011, 12:6. 21219660.
25. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008, 31(4):742-750. 18256071.
26. Walker PP, Calverley PM. The volumetric response to bronchodilators in stable chronic obstructive pulmonary disease. COPD 2008, 5(3):147-152. 18568838.
27. Cerveri I, Pellegrino R, Dore R, Corsico A, Fulgoni P, Van De Woestijne KP, Brusasco V. Mechanisms for isolated volume response to a bronchodilator in patients with COPD. J Appl Physiol 2000, 88(6):1989-1995. 10846010.
28. Anthonisen NR, Lindgren PG, Tashkin DP, Kanner RE, Scanlon PD, Connett JE. Bronchodilator response in the lung health study over 11 yrs. Eur Respir J 2005, 26(1):45-51. 15994388.
29. Albert P, Agusti A, Edwards L, Tal-Singer R, Yates J, Bakke P, Celli BR, Coxson HO, Crim C, Lomas DA, Macnee W, Miller B, Rennard S, Silverman EK, Vestbo J, Wouters E, Calverley P. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax 2012, 67(8):701-708. 22696176.
30. Nagai A, West WW, Thurlbeck WM. The national institutes of health intermittent positive-pressure breathing trial: pathology studies. II. Correlation between morphologic findings, clinical findings, and evidence of expiratory air-flow obstruction. Am Rev Respir Dis 1985, 132(5):946-953. 3904549.
31. Hansen JE. Assessment of bronchoreversibility in severe emphysema. Eur Respir J 2010, 36(4):972. author reply 973, 20889470.
32. Celedon JC, Speizer FE, Drazen JM, Weiss ST, Campbell EJ, Carey VJ, Reilly JJ, Ginns L, Silverman EK. Bronchodilator responsiveness and serum total IgE levels in families of probands with severe early-onset COPD. Eur Respir J 1999, 14(5):1009-1014. 10596682.
33. Palmer LJ, Celedon JC, Chapman HA, Speizer FE, Weiss ST, Silverman EK. Genome-wide linkage analysis of bronchodilator responsiveness and post-bronchodilator spirometric phenotypes in chronic obstructive pulmonary disease. Hum Mol Genet 2003, 12(10):1199-1210. 12719384.
34. Kim V, Pechulis RM, Abuel-Haija M, Solomides CC, Gaughan JP, Criner GJ. Small airway pathology and bronchoreversibility in advanced emphysema. COPD 2010, 7(2):93-101. 20397809.
35. Han MK, Wise R, Mumford J, Sciurba F, Criner GJ, Curtis JL, Han MK, Wise R, Mumford J, Sciurba F, Criner GJ, Curtis JL, Murray S, Sternberg A, Weinman G, Kazerooni E, Fishman AP, Make B, Hoffman EA, Mosenifar Z, Martinez FJ. Prevalence and clinical correlates of bronchoreversibility in severe emphysema. Eur Respir J 2010, 35(5):1048-1056. 19926748.